Phase 4 N=35 Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness
Occasional Sleeplessness
Primary: Mean Latency to Persistent Sleep — 19.1; 27.1 minutes — p=0.0312
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Phase 2 N=34 Chamomile for Chronic Primary Insomnia
Primary Insomnia · Chronic Insomnia
Primary: Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28. — 83.3; 77.5 percentage of time asleep — p=0.21
Phase 3 N=30 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study
Chronic Insomnia · Primary Insomnia
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale
Phase 2 N=39 Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia
Short-term Insomnia
Primary: Total Sleep Time — 382.9; 339.2; 256.2 minutes
Phase 2 N=20 Effect of Background Noise on Sleep Quality
Sleep Onset Insomnia
Primary: Sleep Onset Latency (Mins) — 13; 19 minutes — p=0.011
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=349 Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness
Insomnia · Sleeplessness · Transient Insomnia
Primary: Latency to Persistent Sleep (LPS) — 48.14; 58.84 minutes — p=.1275
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
N/A N=111 Magnesium Nutrition and Sleep Behavior in Older Adults
Nutritional Deficiency · Insomnia
Primary: Global Pittsburgh Sleep Quality Index — 6.30; 6.96 score on a scale
N/A N=30 Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
Nocturia · Hypertension · Sleep Disturbance
Primary: Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention — -0.4; 7.3; 3.9 percentage of daytime mean SBP — p=0.65
Phase 4 N=79 Improving Sleep in Nursing Homes
Sleep Deprivation
Primary: Number of Participants Meeting Good Sleep Latency Criteria — 7; 6 participants — p=0.655
N/A N=105 Investigational Test of a New Sleep Supplement
Sleep · Mood · Cognitive Performance
Primary: Sleep Diary- Sleep Latency — -2.1; -2.53 minutes — p=0.1543
N/A N=27 Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment · Insomnia
Primary: Sleep Latency — 28.51; 47.06 minutes
N/A N=245 The RESTING Insomnia Study: Randomized Controlled Study on Effectiveness of Stepped-Care Sleep Therapy
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
Phase 4 N=20 Treatment of Insomnia and Glucose Metabolism
Sleep · Insomnia · Insulin Resistance
Primary: Plasma Glucose Level at the 120-minute Time Point of a 75g Oral Glucose Tolerance Test
Phase 4 N=20 Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing
Insomnia · Primary Insomnia · Psychophysiologic Insomnia
Primary: Sleep Latency (SL) — 1; 2; 3; 0 participants
Phase 2 N=125 Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
Insomnia
Primary: Percentage of Time Spent in the Combination of Slow Wave Sleep (SWS) and Rapid Eye Movement (REM) Sleep — 43.0; 41.8 Percentage of total sleep time — p=0.0350
Phase 2 N=67 Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
Sleep Disorder · Primary Insomnia
Primary: Wake After Sleep Onset During Hours 3 to 7 Post-dose (WASO 3-7) — -40.19; -48.79; -50.17; -49.34 minutes — p=0.0118
Phase 2 N=40 Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
Insomnia
Primary: Change in Daytime Insomnia Symptoms Scale (DISS) — 65.96; 70.34; 69.22; 72.32 units on a scale
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
Phase 4 N=5 Improving Sleep Quality in Heart Failure
Sleep Disturbance · Heart Failure
Primary: Sleep Latency — -73.3; 21.9 minutes
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
N/A N=15 Blue Blockers at Night and Insomnia Symptoms
Insomnia · Sleep
Primary: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score — 72.64 units on a scale
Phase 4 N=41 Suvorexant and Trauma Related Insomnia
Insomnia · Posttraumatic Stress Disorder
Primary: Change in Insomnia Severity Index Score From Baseline. — 6.8; 8.6 units on a scale — p=<.05
N/A N=226 PERSONAL - Sleep In Breast Cancer
Insomnia · Breast Cancer
Primary: Prevalence of Insomnia in a Cohort of Breast Cancer Patients — 170 Participants
N/A N=149 Insomnia Treatment for Women Veterans
Insomnia
Primary: Number of Participants Completing 5 Behavioral Treatment Sessions — 63; 70 Participants — p==.120